GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (XCNQ:MRMD) » Definitions » Shiller PE Ratio

MariMed (XCNQ:MRMD) Shiller PE Ratio : (As of May. 20, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MariMed Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MariMed Shiller PE Ratio Historical Data

The historical data trend for MariMed's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Shiller PE Ratio Chart

MariMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MariMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MariMed's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MariMed's Shiller PE Ratio falls into.



MariMed Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

MariMed's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, MariMed's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.005/131.7762*131.7762
=-0.005

Current CPI (Mar. 2024) = 131.7762.

MariMed Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.004 100.560 -0.005
201409 -0.121 100.428 -0.159
201412 -0.127 99.070 -0.169
201503 -0.013 99.621 -0.017
201506 -0.012 100.684 -0.016
201509 -0.005 100.392 -0.007
201512 -0.027 99.792 -0.036
201603 -0.004 100.470 -0.005
201606 -0.001 101.688 -0.001
201609 -0.001 101.861 -0.001
201612 0.000 101.863 0.000
201703 -0.001 102.862 -0.001
201706 0.011 103.349 0.014
201709 -0.002 104.136 -0.003
201712 -0.014 104.011 -0.018
201803 -0.014 105.290 -0.018
201806 -0.003 106.317 -0.004
201809 -0.023 106.507 -0.028
201812 -0.052 105.998 -0.065
201903 0.000 107.251 0.000
201906 0.027 108.070 0.033
201909 -0.045 108.329 -0.055
201912 -0.496 108.420 -0.603
202003 -0.014 108.902 -0.017
202006 -0.007 108.767 -0.008
202009 0.006 109.815 0.007
202012 0.017 109.897 0.020
202103 0.013 111.754 0.015
202106 0.024 114.631 0.028
202109 0.013 115.734 0.015
202112 -0.026 117.630 -0.029
202203 0.013 121.301 0.014
202206 0.006 125.017 0.006
202209 0.013 125.227 0.014
202212 0.014 125.222 0.015
202303 -0.003 127.348 -0.003
202306 -0.004 128.729 -0.004
202309 -0.014 129.860 -0.014
202312 -0.027 129.419 -0.027
202403 -0.005 131.776 -0.005

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MariMed  (XCNQ:MRMD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


MariMed Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of MariMed's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MariMed (XCNQ:MRMD) Business Description

Traded in Other Exchanges
Address
10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.
Executives
Jon R. Levine Senior Officer
Timothy Shaw Senior Officer